K. Tryfonidis

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer

Chara Papadaki, Maria Sfakianaki, Georgios Ioannidis et al. · Journal of Thoracic Oncology · 2012 · 74 citations

Medicine, Oncology, Pharmacology +11

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Giuseppe Viale, Femke A. de Snoo, Leen Slaets et al. · Breast Cancer Research and Treatment · 2017 · 62 citations

Medicine, Oncology, Pathology +17

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

Chara Papadaki, Emilia Tsaroucha, L Kaklamanis et al. · British Journal of Cancer · 2010 · 32 citations · Full text

Medicine, Oncology, Pharmacology +15

A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

Niki Karachaliou, N. Ziras, K. Syrigos et al. · Cancer Chemotherapy and Pharmacology · 2012 · 15 citations

Medicine, Oncology, Pharmacology +17

A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer

K. Tryfonidis, Ioannis Boukovinas, Nikolaos Xenidis et al. · The Breast · 2013 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17